Synthetic Cannabinoid Use: A Case Series of Adolescents

Castellanos, Daniel; Singh, Simar; Thornton, Gabriel; Ávila, María Elena Escobar; Moreno, A. Capote

doi:10.1016/j.jadohealth.2011.08.002

Cited by 109 publications

(112 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our case, psychotic symptoms were developed after a short duration of SC use (10 days). It was reported that symptoms related to SC use in adolescent cases were similar to the ones in adults (21). Consistently with the literature, auditory hallucinations and persecution delusions were marked psychotic symptoms in our case, and also Capgras syndrome which was outlined with delusions that his mother and father were replaced by other individuals, was observed.…”

Section: Discussionsupporting

confidence: 92%

“…In the literature, longer durations of SC use as weeks or years were reported in cases who developed SC related psychotic disorder (15,21). In our case, psychotic symptoms were developed after a short duration of SC use (10 days).…”

Section: Discussionmentioning

confidence: 52%

“…In the literature, presence of familial psychotic disorder history was noted in some cases (15,17,23), but there was no previous psychiatric disease in the family history in our case. Castellanos et al (21) reported previous cannabis and alcohol use in 10 out of 11 (91%) of adolescent cases who used SC. In our case, although there was no alcohol abuse history, previous volatile substance use was described.…”

Section: Discussionmentioning

confidence: 99%

“…In the literature, adolescent cases who applied to hospitals for SC use have been increasingly reported (6,17,21). Although it was known that SCs had stronger effects when compared with cannabis, there was no adequate information about pharmacokinetics, and pharmacodynamics of many of the SCs in humans (1,8).…”

Section: Discussionmentioning

confidence: 99%

“…Although it was determined that psychotic symptoms might be triggered in individuals with previous psychotic disorder history while taking SCs (4,23), new onset psychotic symptoms were reported in individuals who had no previous psychotic disorder history (15)(16)(17)(18). In the literature, a few adolescent cases who developed psychotic symptoms after SC use were reported (17,21).…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Capgras syndrome after use of synthetic cannabinoids: an adolescent case

Özer¹,

Çeri²,

Evren³

2016

Dusunen Adam

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 52%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Capgras syndrome after use of synthetic cannabinoids: an adolescent case

Özer¹,

Çeri²,

Evren³

2016

Dusunen Adam

View full text Add to dashboard Cite

“Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report

Papanti

Schifano

Botteon

et al. 2013

Human Psychopharmacology

167

135

View full text Add to dashboard Cite

Objectives The use of synthetic cannabimimetics (SC; "spice" drugs) is increasing, especially among teenagers and young adults. In parallel with this, the number of studies describing intoxication episodes associated with psychotic symptoms in SC users is growing. We present both a systematic review of the related literature and a case report, which seems to highlight the existence of a possible association between SC use and psychosis. Methods Some 223 relevant studies were here identified and reviewed. Out of these, 120 full text articles were assessed for eligibility, and 41 were finally included in the systematic review. Results According to the available data from the studies here identified, SC's average age of users was 22.97 years, and the male/female ratio was 3.16:1. SC compounds most often reported in studies using biological specimen analysis were JWH-018, JWH-073, JWH-122, CP-47,497, and JWH-250. Mounting evidence seemed to suggest that psychotic symptoms such as hallucinations and delusions may occur in acute/chronic SC users. Conclusions Although a clear causal link may not be here identified, the available evidence suggests that SC can trigger the onset of acute psychosis in vulnerable individuals and/or the exacerbation of psychotic episodes in those with a previous psychiatric history.

show abstract

New Drugs of Abuse

et al. 2014

View full text Add to dashboard Cite

Drug abuse is a common problem and growing concern in the United States, and over the past decade, novel or atypical drugs have emerged and have become increasingly popular. Recognition and treatment of new drugs of abuse pose many challenges for health care providers due to lack of quantitative reporting and routine surveillance, and the difficulty of detection in routine blood and urine analyses. Furthermore, street manufacturers are able to rapidly adapt and develop new synthetic isolates of older drugs as soon as law enforcement agencies render them illegal. In this article, we describe the clinical and adverse effects and purported pharmacology of several new classes of drugs of abuse including synthetic cannabinoids, synthetic cathinones, salvia, desomorphine, and kratom. Because many of these substances can have severe or life-threatening adverse effects, knowledge of general toxicology is key in recognizing acute intoxication and overdose; however, typical toxidromes (e.g., cholinergic, sympathomimetic, opioid, etc.) are not precipitated by many of these agents. Medical management of patients who abuse or overdose on these drugs largely consists of supportive care, although naloxone may be used as an antidote for desomorphine overdose. Symptoms of aggression and psychosis may be treated with sedation (benzodiazepines, propofol) and antipsychotics (haloperidol or atypical agents such as quetiapine or ziprasidone). Other facets of management to consider include treatment for withdrawal or addiction, nutrition support, and potential for transmission of infectious diseases.

show abstract

Synthetic Cannabinoid Use: A Case Series of Adolescents

Cited by 109 publications

References 6 publications

Capgras syndrome after use of synthetic cannabinoids: an adolescent case

Capgras syndrome after use of synthetic cannabinoids: an adolescent case

“Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report

New Drugs of Abuse

Contact Info

Product

Resources

About